Skip to main content
. 2018 Jun 12;23(6):1420. doi: 10.3390/molecules23061420

Figure 1.

Figure 1

Structures of isatin-based approved anticancer drugs (II and III), some reported isatin-based hybrids with potent antiproliferative activity against breast cancer (VII–IX), and the target conjugates (4a–n and 7a–d).